Jürgen Cox (Max Planck Institute for Biochemistry (Martinsried/Munich))

Cox, Jürgen (Max Planck 200705 MPI for Biochemistry)

	Organisation	Max Planck Institute for Biochemistry (Martinsried/Munich)
	Group	Max Planck Society for the Advancement of Science
	Product	LTQ Orbitrap™ mass spectrometer

Kinaxo Biotechnologies GmbH. (5/7/07). "Press Release: Kinaxo Expands Technology Platform and Secures Additional Venture Capital". Martinsried.

KINAXO Biotechnologies GmbH is expanding its technology platform to include state-of-the-art mass spectrometry. This will allow KINAXO to better serve the increasing demand of the pharmaceutical industry for chemical proteomics analyses. The new in-house mass spectrometry facility is supported by scientific advisors Jesper Olsen and Jürgen Cox, two experts from the department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry in Martinsried. KINAXO's technical equipment comprises an ultra-sensitive LTQ Orbitrap mass spectrometer from Thermo Fisher Scientific. New lead investor Mountain Partners AG and co-investor KfW provided venture capital to fund KINAXO's technology expansion. Seeding investor High-Tech Gründerfonds as well as KINAXO's shareholders Max Planck Society, BioM AG, Axel Ullrich and Hellmut Kirchner also participated in this financing round.

About KINAXO

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany . We support pharmaceutical and biotechnology companies in their development and optimization of drug leads with clean selectivity profiles. Amongst others KINAXO has ongoing collaborations with Bayer-Schering, UCB Pharma and Johnson & Johnson. KINAXO offers its clients a comprehensive chemical-proteomics technology - known as KinaTorTM - to identify and characterize the interaction of small molecule inhibitors with their protein targets in the physiological context of a cell. This enables a knowledge-driven improvement of drug leads and minimizes the risks of side-effects. Tailored to protein kinases, the KinaTorTM technology represents a highly efficient approach to developing so called targeted kinase inhibitors. Licensing agreements with GPC Biotech AG and the Max Planck Society give us exclusive worldwide rights to use the KinaTorTM technology in contract research activities.

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

Jürgen Cox (Max Planck Institute for Biochemistry (Martinsried/Munich))

Kinaxo Biotechnologies GmbH. (5/7/07). "Press Release: Kinaxo Expands Technology Platform and Secures Additional Venture Capital". Martinsried.

More documents for Jürgen Cox